Skip to main content

Table 2 Univariate analysis according to baseline clinical parameters

From: A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

   OS, mo* 95% CI P
Previous gastrectomy No 6.7 5.3 to 8.2 .660
  Yes 6.7   
Gender Male 7.1 5.9 to 8.4 .464
  Female 6.6 5.9 to 7.3  
Age < median 7.1 5.9 to 8.4 .243
  ≥ median 6.5 5.9 to 7.3  
Response to first-line chemotherapy No 6.4 5.5 to 7.2 .432
  Yes 7.1 5.9 to 8.4  
Treatment-free interval < median 6.7 5.8 to 7.6 .863
  ≥ median 6.8 5.4 to 8.1  
Performance status 0 or 1 7.1 6.2 to 8.1 .001
  ≥ 2 5.4 3.8 to 7.1  
Albumin < median 6.5 5.2 to 7.5 .553
  ≥ median 7.1 5.9 to 8.3  
Alkaline phosphatase < median 6.5 5.7 to 7.4 .886
  ≥ median 7.1 5.6 to 8.6  
Bilirubin < median 6.2 5.3 to 7.1 .766
  ≥ median 7.1 5.9 to 8.4  
Calcium < median 7.2 6.0 to 8.3 .210
  ≥ median 5.9 5.1 to 6.8  
Hemoglobin < median 5.8 5.6 to 6.4 .004
  ≥ median 8.1 7.1 to 9.1  
No. of involved site(s) 1 6.7 5.5 to 8.0 .225
  ≥ 2 6.4 5.4 to 7.3  
Liver metastasis No 7.4 5.2 to 9.6 .497
  Yes 6.6 5.8 to 7.5  
Bone metastasis No 8.4 5.2 to 11.6 .793
  Yes 6.6 5.9 to 7.4  
Ascites No 7.1 6.2 to 8.1 .038
  Yes 4.7 3.5 to 5.9  
Bone marrow involvement No 6.7 5.9 to 7.6 .555
  Yes 5.0 2.5 to 7.6  
Weight loss No 6.7 5.8 to 7.5 .853
  Yes 6.6 3.4 to 9.9  
  1. * OS, median overall survival; 95% CI, 95% confidence interval.